Key facts
- Emerald’s last known valuation is $8.1M (Jan 2026).
- It has raised $2.3M; the latest was Seed Round ($1.9M) in Jan 2026.
- Notable investors include Innovate UK, Granatus Ventures, Boost Capital Partners, Harry Glorikian, Jane Austin — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Emerald
- ·The full record, as it builds
Funding rounds
No funding rounds for Emerald are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Emerald
Developer of a preventive health membership service platform designed to support early detection, ongoing monitoring, and data-driven personal health management. The company's platform integrates lab-based biomarker testing, clinical assessments, lifestyle and wearable data, and personalized action plans reviewed by medical professionals, enabling the preventive healthcare market with continuous health insights, consolidated data access, structured guidance, and improved long-term decision-making based on comprehensive biological information.
- Sector
- Information Technology
- HQ
- London, United Kingdom
- Founded
- 2024
- Employees
- 17
- Website
- withemerald.com/
- Ownership
- Privately Held (backing)
Emerald doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Emerald shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Emerald in its N-PORT filings yet. We sweep new filings monthly.